Background
The diagnosis of paroxysmal nocturnal hemoglobinuria (PNH) relies on flow cytometric demonstration of loss of glycosyl‐phosphatidyl inositol (GPI)‐anchored proteins from red blood cells (RBC) and white blood cells (WBC). High‐sensitivity multiparameter assays have been developed to detect loss of GPI‐linked structures on PNH neutrophils and monocytes. High‐sensitivity assays to detect PNH phenotypes in RBCs have also been developed that rely on the loss of GPI‐linked CD59 on CD235a‐gated mature RBCs. The latter is used to delineate PNH Type III (total loss of CD59) and PNH Type II RBCs (partial loss of CD59) from normal (Type I) RBCs. However, it is often very difficult to delineate these subsets, especially in patients with large PNH clones who continue to receive RBC transfusions, even while on eculizumab therapy.
Methods
We have added allophycocyanin (APC)‐conjugated CD71 to the existing CD235aFITC/CD59PE RBC assay allowing simultaneous delineation and quantification of PNH Type III and Type II immature RBCs (iRBCs).
Results
We analyzed 24 medium to large‐clone PNH samples (>10% PNH WBC clone size) for PNH Neutrophil, PNH Monocyte, Type III and Type II PNH iRBCs, and where possible, Type III and Type II PNH RBCs. The ability to delineate PNH Type III, Type II, and Type I iRBCs was more objective compared to that in mature RBCs. Additionally, total PNH iRBC clone sizes were very similar to PNH WBC clone sizes.
Conclusions
Addition of CD71 significantly improves the ability to analyze PNH clone sizes in the RBC lineage, regardless of patient hemolytic and/or transfusion status.